DEALS: Schering-Plough buys Organon for $14.4B


Schering-Plough buys Organon for $14.4B


DEALS

WHO

WITH

WHAT

SCOOP

Schering-Plough

Akzo Nobel

$14.4B sale

The deal gives Schering-Plough the world's third-largest maker of birth control pills and an overnight boost of 50 percent to its revenue line.

Merck

Avalon Pharmaceuticals

$200M development deal

Avalon agreed to use its technology to identify a compound that can block the activity of an undisclosed protein involved in the development of cancer.

Eli Lilly

Hypnion

Buyout

Eli Lilly is buying Hypnion, a Lexington, MA-based biotech company that has specialized in developing sleep disorder drugs.

Takeda Pharmaceutical

Paradigm Therapeutics

Buyout

Paradigm has a pipeline of targets for pain, central nervous system disorders, prostate and breast cancer, diabetes and obesity.

Oxford BioMedica

Oxxon Therapeutics

Buyout

Oxxon Therapeutics is being acquired by Oxford BioMedica, which has been developing gene-based therapeutic vaccines for cancer and neurotherapy.

Organon

Acrux

Development deal

Australia-based drug delivery company Acrux has teamed up with Organon to develop and market contraceptives delivered through the skin using Acrux's spray technology.

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.